Growth momentum Teknova’s Q1 2026 revenue grew 13% year over year and the company reiterates full-year revenue guidance, signaling a scalable demand for their life sciences reagents and potential upsell opportunities across RUO to GMP transitions.

AI enhanced ordering Launch of Build-Tek, an AI powered reagent configurator, creates a compelling cross sell to customers needing rapid, complex custom product configurations, reducing quote cycles and appealing to high-complexity therapy and diagnostics programs.

GMP readiness Teknova emphasizes a modular manufacturing platform capable of supporting GMP grade reagents alongside research grade, offering sales opportunities to biotechs advancing from discovery to clinical development and commercialization.

Expansion readiness With over 200,000 square feet of facilities and a broad product slate (agar plates, culture media, buffers, reagents, water), Teknova can scale to meet increasing demand from cell and gene therapy developers and diagnostic manufacturers.

Financial signals Annual revenue target range and a recent positive earnings trajectory, plus a stated funding base, suggest stability for expanding account coverage, field sales, and strategic partnerships with mid-market biotech firms seeking reliable reagent suppliers.